111 related articles for article (PubMed ID: 31524891)
1. Drug-resistance mechanisms of three mutations in anaplastic lymphoma kinase against two inhibitors based on MM/PBSA combined with interaction entropy.
Xiao Z; Cong Y; Huang K; Zhong S; Zhang JZH; Duan L
Phys Chem Chem Phys; 2019 Oct; 21(37):20951-20964. PubMed ID: 31524891
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
[TBL] [Abstract][Full Text] [Related]
3. Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.
Chen J; Wang W; Sun H; Pang L; Yin B
J Comput Aided Mol Des; 2020 Dec; 34(12):1289-1305. PubMed ID: 33073300
[TBL] [Abstract][Full Text] [Related]
4. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Shaw AT; Friboulet L; Leshchiner I; Gainor JF; Bergqvist S; Brooun A; Burke BJ; Deng YL; Liu W; Dardaei L; Frias RL; Schultz KR; Logan J; James LP; Smeal T; Timofeevski S; Katayama R; Iafrate AJ; Le L; McTigue M; Getz G; Johnson TW; Engelman JA
N Engl J Med; 2016 Jan; 374(1):54-61. PubMed ID: 26698910
[TBL] [Abstract][Full Text] [Related]
5. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
Wu X; Wang Y; Wan S; Zhang J
J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
[TBL] [Abstract][Full Text] [Related]
6. A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants.
He M; Li W; Zheng Q; Zhang H
J Cell Biochem; 2018 Jul; 119(7):5332-5342. PubMed ID: 29323742
[TBL] [Abstract][Full Text] [Related]
7. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
Ai X; Shen S; Shen L; Lu S
Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
[TBL] [Abstract][Full Text] [Related]
8. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.
Sun HY; Ji FQ
Biochem Biophys Res Commun; 2012 Jun; 423(2):319-24. PubMed ID: 22659414
[TBL] [Abstract][Full Text] [Related]
9. Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR.
Yoshida R; Sasaki T; Umekage Y; Tanno S; Ono Y; Ogata M; Chiba S; Mizukami Y; Ohsaki Y
BMC Cancer; 2018 Nov; 18(1):1136. PubMed ID: 30453899
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.
Guan J; Wolfstetter G; Siaw J; Chand D; Hugosson F; Palmer RH; Hallberg B
Oncotarget; 2017 Feb; 8(7):11566-11578. PubMed ID: 28030793
[TBL] [Abstract][Full Text] [Related]
12. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
13. Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.
Sun H; Li Y; Li D; Hou T
J Chem Inf Model; 2013 Sep; 53(9):2376-89. PubMed ID: 23952683
[TBL] [Abstract][Full Text] [Related]
14. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
15. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.
Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558
[TBL] [Abstract][Full Text] [Related]
16. Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling.
Chen J; Wang J; Zhu W
Phys Chem Chem Phys; 2017 Nov; 19(44):30239-30248. PubMed ID: 29109998
[TBL] [Abstract][Full Text] [Related]
17. Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
Yun MR; Lim SM; Kim SK; Choi HM; Pyo KH; Kim SK; Lee JM; Lee YW; Choi JW; Kim HR; Hong MH; Haam K; Huh N; Kim JH; Kim YS; Shim HS; Soo RA; Shih JY; Yang JC; Kim M; Cho BC
Cancer Res; 2018 Jun; 78(12):3350-3362. PubMed ID: 29669761
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
[TBL] [Abstract][Full Text] [Related]
19. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
